Zedaunor

Daunorubicin is also used with other chemotherapy drugs to treat a certain type of acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells).

Daunorubicin is in a class of medications called anthracyclines.

It works by slowing or stopping the growth of cancer cells in your body.

Daunorubicin comes as a solution (liquid) or as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility along with other chemotherapy medications.

When daunorubicin is used to treat AML, it is usually injected once a day on certain days of your treatment period.

When daunorubicin is used to treat ALL, it is usually injected once a week.

The length of treatment depends on

• The types of drugs you are taking
• How well your body responds to them
• The type of cancer you have

To ascertain the efficacy and safety of daunorubicin combined with cytarabine comparing with idarubicin combined with cytarabine as a standard induction therapy for acute myeloid leukemia by a meta-analysis.

To ascertain the efficacy and safety of daunorubicin combined with cytarabine comparing with idarubicin combined with cytarabine as a standard induction therapy for acute myeloid leukemia by a meta-analysis.

Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.

In order to eradicate the leukemic cells and induce a complete remission, a profound suppression of the bone marrow is usually required.

Evaluation of both the peripheral blood and bone marrow is mandatory in the formulation of appropriate treatment plans.

It is recommended that the dosage of Cerubidine (daunorubicin) be reduced in instances of hepatic or renal impairment.

For example, using serum bilirubin and serum creatinine as indicators of liver and kidney function.